Biotech growth driven by Illumina's genome sequencing and CRISPR's gene editing innovations

The biotech sector's growth hinges on two key players: Illumina, which provides large-scale genome sequencing, and CRISPR Therapeutics, which develops gene-editing therapies. Illumina reported steady revenue growth and projects 4-6% revenue increase in 2026, supported by consumables and new acquisitions. CRISPR's lead therapy CASGEVY showed strong revenue gains in 2025, with an expanding pipeline targeting various diseases. Together, they form a complementary cycle where better genetic data enables more precise gene editing, driving the personalized medicine revolution. Investors benefit from owning both to capture steady data-driven growth and high-upside therapeutic potential despite regulatory and market risks.